Development of matrix metalloproteinase inhibitors in cancer therapy.
about
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?Human trophoblast function during the implantation processSelective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal CancerPaclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafishPutting tumours in contextLysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expressionProstate cancer in bone: importance of context for inhibition of matrix metalloproteinasesChemical biology of tetracycline antibioticsThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Systems and Chemical Biology, and has undergone the Journal's usual peer review process.PDGF‑stimulated dispersal of cell clusters and disruption of fibronectin matrix on three-dimensional collagen matrices requires matrix metalloproteinase-2.Diorganotin(IV) derivatives of N-methyl p-fluorobenzo-hydroxamic acid: preparation, spectral characterization, X-ray diffraction studies and antitumor activity.Present and potential future issues in glioblastoma treatment.Nitric oxide modulates caveolin-1 and matrix metalloproteinase-9 expression and distribution at the endothelial cell/tumor cell interface.The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphomaInhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia.Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.Demand for Zn2+ in acid-secreting gastric mucosa and its requirement for intracellular Ca2+.A novel synthetic oleanane triterpenoid suppresses adhesion, migration, and invasion of highly metastatic melanoma cells by modulating gelatinase signaling axis.Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis.Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method.Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors.Matrix metalloproteinases in tumorigenesis: an evolving paradigm.Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cellsChanging boundaries in the treatment of malignant gliomas.Chemotherapy for the treatment of metastatic brain tumors.Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface.Detection of protease activities by flash chronopotentiometry using a reversible polycation-sensitive polymeric membrane electrode.The changing role of pathology in breast cancer diagnosis and treatment.Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9Advances in molecular therapies in patients with brain tumors.Extracellular proteases as targets for drug developmentTherapeutic potential of active stent coating.What is the future of targeted therapy in rheumatology: biologics or small molecules?Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules.Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
P2860
Q24794969-45BE23EE-F0CC-48B7-B22C-4CD8C928D899Q24811501-F8F2588D-FC60-46F9-8BD8-C74E701B27C1Q27306938-18FBACCB-070A-4139-85F4-38447A1499E8Q27316580-E84DF1BD-F47B-453C-A0C8-711476E210FCQ28207789-5DF48497-A94B-4715-BB38-4FE00439ABD6Q28299091-663C828D-2D7C-43C8-8886-F62E477D788DQ28344383-37954699-C1D1-46E0-B451-4A5EE96E2465Q29030024-8FF7A2F8-5B3F-46CF-B262-7D98920ABB34Q30627162-8906F352-DC1E-486D-BF02-1F0F238AC679Q30656931-265B59C6-803F-4A8A-AF5A-72A633C44510Q31043603-196D01B9-8EDF-4144-985D-4B5F87D0E6F1Q33200943-5DBD92FF-6A75-40B9-B203-3218025D03B9Q33311418-AC9A4B52-90AF-44C2-A884-5B4E3A45F683Q33511198-660CFCED-8CD2-4174-A42C-6F273AF80F24Q33660754-704FBD3D-BEF9-412C-A851-CB00A2B0602CQ33758871-993098C5-97AD-43E5-9BB3-44CFEE5DB603Q33941224-CD96EFC5-F99A-4B59-B6EF-C33117F0CBE0Q34022900-3630B771-116C-4F1D-BF42-491D8971F0B6Q34054522-8C17CEE8-FC03-4109-BA37-E2F8BDF674ECQ34110118-EA8B1785-5011-4F69-A850-4426BFBFBCF3Q34175711-395440B9-4AAC-4CE7-88EA-752D0BBB5492Q34199345-A2FAF362-7A18-41B6-AD4A-8548BF47E1B9Q34510788-FECABF2F-EAB4-4992-B705-8B20302FCB74Q34540533-83B5FB85-C8DE-415C-9D8F-CDD864E56402Q34616803-58D5F462-EA80-468A-8BCC-7D86755A7257Q34703798-41D0DDA0-FD37-458C-9513-6ECA25065580Q34734197-C004D918-71BF-4A90-AF6B-BD4472693DACQ34969177-FD4C0519-F1BA-495A-8DFE-771572B23642Q35021987-73231F2F-433F-42E4-8308-5BB6B86AF0E6Q35074826-80902E49-D1C5-4F78-9481-6DBCCEEB7F8DQ35082260-11AE70C5-B091-4688-B015-EF0336DEDE9AQ35112695-5D73986B-2F99-4B0A-9FA3-18EB6283CBF4Q35113656-3B7F409A-1A86-4160-BC2E-80A0422F7913Q35116202-F503CC2F-ECA5-48AF-B4AE-DBF046A601C7Q35117070-F0D11070-DE8B-42DE-BA5C-61B0EFAA5B02Q35118364-8F9D64D7-45B1-4446-96C5-BCE4114335BDQ35143943-85084B19-9303-4FC7-9DF7-544B1A3184F3Q35157568-9DC3B58E-B58E-440B-B3E1-2F547B807543Q35161738-4584F4D5-3154-47B4-BB76-C0E6EDF61087Q35187217-9B7E3A61-39C5-4374-AB92-3F2E2B529E14
P2860
Development of matrix metalloproteinase inhibitors in cancer therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Development of matrix metalloproteinase inhibitors in cancer therapy.
@ast
Development of matrix metalloproteinase inhibitors in cancer therapy.
@en
type
label
Development of matrix metalloproteinase inhibitors in cancer therapy.
@ast
Development of matrix metalloproteinase inhibitors in cancer therapy.
@en
prefLabel
Development of matrix metalloproteinase inhibitors in cancer therapy.
@ast
Development of matrix metalloproteinase inhibitors in cancer therapy.
@en
P356
P1476
Development of matrix metalloproteinase inhibitors in cancer therapy
@en
P2093
S G Eckhardt
P304
P356
10.1093/JNCI/93.3.178
P407
P577
2001-02-01T00:00:00Z